Clinical Trial

Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab

Completed Phase 4
View on ClinicalTrials.gov →
Summary
This study is designed to evaluate the safety after switching to garadacimab from another prophylactic hereditary angioedema (HAE) treatment (marketed kallikrein \[KK\] inhibitor or plasma-derived C1-esterase inhibitor \[pdC1INH\]prophylactic) when administered once monthly for approximately 3 months in participants aged greater than or equal to (\>=) 12 years with HAE.
Protocol Amendment History 3 changes
critical Trial completed 2026-07-24
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-15
notable Enrollment reduced: 30 -> 18 participants 2026-05-15
Trial Details
NCT Number NCT06806657
Lead Sponsor CSL Behring
Conditions Hereditary Angioedema
Enrollment 18 participants
Start Date 2025-04-28
Primary Completion 2026-06-29 (estimated)
Study Completion 2026-06-29 (estimated)
Updated on ClinicalTrials.gov 2026-07-23